IRIS UniCatt

Bacigalupo, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.738
EU - Europa 2.414
AS - Asia 2.031
SA - Sud America 453
AF - Africa 46
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 4
Totale 7.699
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.685
CN - Cina 754
SG - Singapore 666
SE - Svezia 646
IT - Italia 559
BR - Brasile 398
DE - Germania 258
FR - Francia 197
IE - Irlanda 188
ID - Indonesia 156
TR - Turchia 134
IN - India 113
GB - Regno Unito 98
RU - Federazione Russa 98
FI - Finlandia 89
KR - Corea 69
PL - Polonia 66
UA - Ucraina 66
CA - Canada 36
HK - Hong Kong 26
NL - Olanda 26
BE - Belgio 25
AT - Austria 21
CI - Costa d'Avorio 20
JP - Giappone 19
AR - Argentina 17
CZ - Repubblica Ceca 16
IR - Iran 14
AU - Australia 13
CO - Colombia 12
ES - Italia 12
MX - Messico 12
BD - Bangladesh 9
IQ - Iraq 8
CL - Cile 7
EC - Ecuador 7
RO - Romania 7
TW - Taiwan 7
VN - Vietnam 7
ZA - Sudafrica 7
EG - Egitto 6
IL - Israele 6
VE - Venezuela 6
CH - Svizzera 5
DK - Danimarca 5
MA - Marocco 5
PT - Portogallo 5
KG - Kirghizistan 4
PK - Pakistan 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
AM - Armenia 3
DZ - Algeria 3
GE - Georgia 3
HU - Ungheria 3
JO - Giordania 3
KE - Kenya 3
PH - Filippine 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
EU - Europa 2
HR - Croazia 2
JM - Giamaica 2
LI - Liechtenstein 2
LK - Sri Lanka 2
LT - Lituania 2
NO - Norvegia 2
PY - Paraguay 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BJ - Benin 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
EE - Estonia 1
GR - Grecia 1
IM - Isola di Man 1
IS - Islanda 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
MY - Malesia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
QA - Qatar 1
SA - Arabia Saudita 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 7.699
Salva come PNG Salva come JPEG
Città #
Chandler 555
Singapore 389
Dublin 186
Ashburn 179
Jakarta 153
Izmir 120
Ann Arbor 119
Wilmington 106
Nanjing 98
Milan 89
Rome 89
Beijing 79
San Mateo 74
Hefei 71
Moscow 71
Jacksonville 69
Seoul 67
Fairfield 65
Boston 62
Warsaw 59
Los Angeles 58
Cattolica 56
Houston 54
Nanchang 53
Princeton 53
Hyderabad 50
Florence 49
New York 49
Frankfurt am Main 41
Seattle 41
Dearborn 38
Chicago 36
Lawrence 36
Redwood City 36
São Paulo 36
Munich 35
Marseille 34
Helsinki 33
Woodbridge 33
Boardman 32
Fuzhou 32
Brussels 24
Hebei 23
Bremen 22
Kunming 22
Redmond 22
The Dalles 22
Cambridge 21
Lancaster 21
Abidjan 20
Jiaxing 20
Nuremberg 20
Shanghai 20
Shenyang 20
Hong Kong 19
Paris 19
Changsha 18
Hangzhou 18
Guangzhou 17
Mountain View 16
Tianjin 16
Pune 15
Toronto 14
Arezzo 13
London 13
Belo Horizonte 12
Düsseldorf 12
Santa Clara 12
Brno 11
Council Bluffs 11
Lappeenranta 11
Turin 11
Washington 11
Bologna 10
Mcallen 9
Norwalk 9
Phoenix 9
Portsmouth 9
Zhengzhou 9
Andover 8
Porto Alegre 8
San Francisco 8
Turku 8
Bexley 7
Bogotá 7
Brasília 7
Charlotte 7
Falkenstein 7
Lauterbourg 7
Ottawa 7
Rio de Janeiro 7
Tokyo 7
Vienna 7
Worcester 7
Augusta 6
Campinas 6
Edinburgh 6
Goiânia 6
Naples 6
Tampa 6
Totale 4.331
Salva come PNG Salva come JPEG
Nome #
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial 326
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies:uptade consensus recommendations of the European Society for Blood 231
Rabbit ATG/ATLG in preventing graft-versus-host disease after allogenic stem cell transplantation: consensus-besed recommendations by an international expert panel 198
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 99
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 95
Nasopharynxkarzinom in einem europäischen Gebiet mit geringer Inzidenz: Eine prospektive Beobachtungsanalyse der Kopf- und Hals-Studiengruppe der Italienischen Gesellschaft für Radioonkologie (AIRO) 87
Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation. 85
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 84
A closer look at permissive HLA mismatch 84
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 84
UGT1A1 Polymorphism and Mortality Outcome after Allogeneic Stem Cell Transplantation with Busulfan Based Regimen 82
Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers 81
Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal 81
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 79
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 79
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 78
A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study 78
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study 78
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 78
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 77
Unrelated cord blood transplantation and post-transplant cyclophosphamide 77
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 77
Alternative donor transplants for severe aplastic anemia: current experience 76
Bone marrow haploidentical transplant with post-transplantation cyclophosphamide :does graft cell content have an impact on main clinical outcomes? 76
ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- And Long-term Outcomes 76
Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation 75
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study 72
Nutritional status and quality of life in adults undergoing allogeneic hematopoietic stem cell transplantation 72
Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia 71
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. 71
Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation? 70
Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant 70
Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: Monocentric observational study and review of the literature 70
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD 69
Integrating transplantation with antibodies and genetically modified T-cell therapies 69
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation 69
Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes? 69
Antithymocyte globulin in the conditioning regimen: why not? 68
Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia 68
Unrelated cord blood transplantation and post-transplant cyclophosphamide 67
Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: A registry study by the European society for blood and marrow transplantation 67
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome 66
Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression 65
Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia 65
Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation 63
Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: A retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) 63
Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups 62
Menstrual patterns, fertility and main pregnancy outcomes after allogeneic haematopoietic stem cell transplantation 62
Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome 61
Preoperative autologous blood donation in adult bone marrow donors: reappraisal of a single-centre experience 61
Severe cmv infection after chemo-immunotherapy with dose- reduced bendamustine and rituximab in a mantle cell lymphoma old patient 61
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 60
Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: A retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation 60
Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients 60
Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All-Trans Retinoic Acid: A Monocentric Experience 58
Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: A report from the acute leukemia working party of the EBMT 58
Alternative donor transplants for severe aplastic anemia: Current experience 58
Failure to effectively treat chronic graft-versus-host disease: a strong call for prevention 57
RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT 57
CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation 57
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells 56
Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis 56
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation 56
A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study 56
Haploidentical bone marrow transplantation for AML in remission following TBF conditioning: a long-term follow up 56
Post-transplant cyclophosphamide versus antithymocyte-globulin as graft versus host disease prophylaxis in haploidentical transplant 55
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation 55
Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis 54
PURLs: Light therapy for nonseasonal major depressive disorder? 54
full donor chimerism after allogenic hematopoietic stem cells transplant for myelofibrosis the role of the conditioning regiment 54
Days alive outside hospital and readmissions in patients undergoing allogeneic transplants from identical siblings or alternative donors 54
Long-term survival in a patient with head and neck paraganglioma treated with tailored modalities for 20 years: a case report 53
Allogeneic stem cell transplantation for nonmalignant diseases 52
Second haploidentical stem cell transplantation for primary graft failure 52
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 50
Acute erythroid leukemia with TP53 mutation and BCR/ABL1: challenges in classification and management 50
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 50
First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012 50
Reducing infectious complications after allogeneic stem cell transplant 50
Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients 49
Failure to effectively treat chronic graft-versus-host disease: A strong call for prevention 49
Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients 48
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 48
Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet 47
Preoperative autologous blood donation in adult bone marrow donors: reappraisal of a single-centre experience 47
Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study 45
Steroid treatment of acute graft-versus-host disease grade I: A randomized trial 45
Acute graft versus host disease 1976-2020: reduced incidence and predictive factors 44
Extending long term follow up of patient with acute myeloid leukemia after autologous stem cell transplantation: Disclosing late mortality and causes of death 43
Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All-Trans Retinoic Acid: A Monocentric Experience 42
HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide 42
Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. 42
THE IMPACT OF EDUCATION ON PATIENTS' PSYCHOEMOTIONAL STATUS DURING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTRE PROSPECTIVE STUDY BY THE GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO 41
impact of donor age and kinship on clinical outcomes after T cell-replete haploidentical transplantation with PT-Cv 41
Post-transplant cyclophosphamide with Sirolimus or Cyclosporine for GvHD prophylaxis in matched related and unrelated transplantation: a two-center analysis on 213 consecutive patients 40
Peripheral Blood Allogeneic Stem Cell Mobilization: Can We Predict a Suboptimal Mobilization? 40
HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide 40
Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review 39
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 38
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy 38
Totale 6.738
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.891
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.891
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202052 0 0 0 0 0 0 0 0 0 0 0 52
2020/2021402 43 51 7 17 54 37 18 9 60 24 65 17
2021/2022744 72 12 31 31 49 15 15 116 49 72 129 153
2022/20231.746 260 228 137 243 140 215 79 117 169 50 85 23
2023/20241.169 41 262 66 63 35 115 80 83 39 82 133 170
2024/20252.505 74 84 212 119 184 87 103 98 358 272 629 285
Totale 7.946